Conversion of the sodium channel activator aconitine into a potent α7‐selective nicotinic ligand

Authors:
  • BPBarry V.L. Potter
    Barry V.L. Potter

Abstract
Methyllycaconitine (MLA) is a competitive antagonist of nicotinic acetylcholine receptors, with a remarkable preference for neuronal [125I]αBgt binding sites. We have begun to investigate the structural basis of its potency and subtype selectivity. MLA is a substituted norditerpenoid alkaloid linked to a 2‐(methylsuccinimido)benzoyl moiety. Hydrolysis of the ester bond in MLA to produce lycoctonine diminished affinity for rat brain [125I]αBgt binding sites 2500‐fold and abolished affinity for [3H]nicotine and muscle [125I]αBgt binding sites. The voltage‐gated Na+ channel activator aconitine, also a norditerpenoid alkaloid, but with significant structural differences from lycoctonine, displayed comparable weak or absent nicotinic activity. Addition of a 2‐(methylsuccinimido)benzoyl sidechain to O‐demethylated aconitine, to mimic MLA, abolished Na+ channel activation and conferred nanomolar affinity for brain [125I]αBgt binding sites, comparable to that of MLA. We propose that the ester‐linked 2‐(methylsuccinimido)benzoyl group is necessary for nicotinic potency, but α7 selectivity resides in the norditerpenoid core of the molecule.

This publication has 12 references indexed in Scilit: